- Research article
- Open Access
The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL
BMC Cardiovascular Disorders volume 21, Article number: 41 (2021)
Lp(a) and LDL-C are both risk factors of atherosclerotic cardiovascular disease (ASCVD). But there was a contradiction point in LDL-C and Lp(a) control. The appropriate level of LDL-C and Lp(a) in the prevention of ASCVD is still pending.
To investigate the correlation of Lp(a) and coronary atherosclerotic lesion, and find out the balance point in LDL-C and Lp(a) control.
3449 patients were divided to coronary atherosclerotic heart disease (CAHD) Group and Non-CAHD Group based on the result of coronary angiography. The clinical characteristics were compared, and Logistic regressions were applied to find the CAHD risk factors in total, High-LDL-C Group (LDL-C ≥ 100 mg/dL) and Low-LDL-C Group (LDL-C < 100 mg/dL) patients. Spearman correlation analysis of Lp(a), LDL-C and Gensini Score was performed in patients with different LDL-C concentration.
Except male and diabetes, the traditional CAHD risk factors were well matched between two groups. But triglyceride, LDL-C and Lp(a) were higher, HDL-C and Apo-A1 were lower in CAHD group (2771). In the Logistic regression analysis, diabetes, LDL-C and Lp(a) are risk factors of CAHD in all patients, while in High-LDL-C Group, they were age, LDL-C, non-HDL-C and ApoB, in Low-LDL-C Group, they were age, Lp(a) and ApoB. Lp(a) correlated with Gensini with coefficient r = 0.41 in all patients, 0.67 in Low-LDL-C Group and 0.32 in High-LDL-C Group. The coefficient r for Lp(a) and Gensini decreased, while the r for LDL-C and Gensini increased with LDL-C concentration increasing. The two fitted lines of rs crossed at LDL-C = 2.7 mmol/L (104 mg/dL).
Lp(a) was the risk factor of CAHD in patients with LDL-C < 100 mg/dL. The correlation between Lp(a) and Gensini was influenced by LDL-C concentration, and the correlation was stronger than LDL-C when LDL-C < 104 mg/dl.
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and low-density lipoprotein cholesterol (LDL-C) is the well-established risk factor of ASCVD. The epidemiological and Mendelian randomization studies [1, 2] had shown that serum LDL-C level was correlated to ASCVD risk and had significant impact on the clinical outcomes. LDL-C lowering therapies had been proved to reduce ASCVD risk regardless of the patients’ background [3,4,5,6]. But the data of 13,167 patients from JUPITER , LIPID  and AIM-HIGH  showed 61% more risk of major adverse cardiovascular event (MACE) in patients with higher lipoprotein (a) (Lp(a)) level than those with similar LDL-C level, but lower Lp(a). That indicated Lp(a) may be another ASCVD risk factor needed to be taken seriously. The relation between Lp(a) and ASCVD has been confirmed by at least 3 meta-analyses [10,11,12] and recently published result from ODYSSEY Outcomes . The analysis of the Copenhagen City Heart Study and Copenhagen General Population Study showed a higher cardiovascular disease (CVD) risk when Lp(a) > 30 mg/dL . But there was a contradiction point in LDL-C and Lp(a) control, as statin, the most widely used LDL-C-lowering agent in the world, leading to 15–37% ASCVD risk reduction, could increase Lp(a) by 8.5–19.6% [4, 15]. The clinical benefit of LDL-C lowering with statin could be diminished with the Lp(a) increasing effect. Besides, the optimal clinical control points of LDL-C and Lp(a) is still pending. In this study, we tried to find the relationship between LDL-C, Lp(a) and coronary atherosclerotic lesion in a group of patients with exact evidence of coronary atherosclerosis, and compared correlation strengths within different LDL-C concentrations to find out the balance point of LDL-C and Lp(a) in ASCVD prevention.
This was a single-center cross-sectional clinical study of the patients with the diagnosis of coronary atherosclerotic heart disease (CAHD) and performed coronary angiography (CAG) in our medical center. The clinical data and serum samples were collected from patients matching the inclusion and exclusion criteria. Inclusion criteria: (1) Age > 18 years; (2) Conducted CAG between June 2018 and September 2019; (3) Clear awareness, able to sign informed consent and willing to take blood measurements. Exclusion criteria: (1) Previous percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG); (2) Unstable hemodynamics or left ventricular ejection fraction (LVEF) less than 30%; (3) Severe progressive diseases such as tumors; (4) Rheumatoid or systemic diseases such as sepsis; (5) Cirrhosis or decompensated liver function (Child–Pugh Score > 6); (6) abnormal renal function(estimated glomerular filtration rate < 60 mL/min/1.73m2); (7) women of pregnancy and childbearing age. This study is approved by the ethics committee and conducted with signed consent of all participants.
Patients with any coronary stenosis ≥ 50% were divided to CAHD Group, with all coronary stenosis < 50% were divided to Non-CAHD Group according to CAG results (Fig. 1). The CAGs were performed for patients who had typical or untypical unstable angina pectoris along with myocardial ischemic changes in electrocardiogram, for example, single or multiple leads/territories ST-segment depression/elevation ≥ 1 mm, increased hyperacute T wave amplitude with prominent symmetrical T waves, pathologic Q waves, cardiac arrhythmias, intraventricular bundle branch blocks, atrioventricular conduction delays, loss of precordial R wave amplitude, etc. Clinical characters and lipid index were compared between the two groups. The clinical characters were collected from medical record system once included in this study and the lipide test results came from clinical standardization laboratory. As most patients (95.3%) are at moderate- or low-risk of CVD according to the 2019 ESC/EAS Guidelines for the management of dyslipidemias , we also subdivided patients with the recommended LDL-C concentration and performed subgroup analysis in High-LDL-C Group (LDL-C ≥ 100 mg/dL) and Low-LDL-C Group (LDL-C < 100 mg/dL). Logistic regression analyses were conducted in all patients and subgroups. Spearman correlations were performed to determine the relationship between Lp(a) and Gensini Score. We also conducted Spearman correlation analysis of Lp(a)-Gensini and LDL-C-Gensini in patients with different LDL-C intervals and draw simple dot plots with fitted lines to determine the trends.
Coronary atherosclerosis lesion and Gensini score
The severity of coronary atherosclerosis lesion was evaluated with Gensini Score , which was calculated according to the result of CAG. It was developed to quantitative the severity of the coronary lesions by 3 main parameters: severity score, region multiplying factor and collateral adjustment factor.
Blood samples collecting and LDL-C, Lp(a) measurement
Fasting venous blood samples were collected before CAG. All samples were centrifugated and stored at − 70 °C. LDL-C was measured in mg/dL by beta quantification. Lp(a) was measured in nmol/L by particle-enhanced turbidimetric immunoassay with Tina-quant Lipoprotein (a) Gen.2 (Latex) (LPA2) Roche® on Cobas system.
Qualitative items were presented as n (%) and quantitative item was presented as mean ± SD. Independent sample t-test was used to determine the difference between quantitative items in different groups and Pearson chi square test was used for the qualitative items. Binary logistic regression was used to evaluate the effects of different variables on CAHD in total patients and subgroup analysis. Before binary logistic regression, whether the logit transformation values of continuous independent variables and dependent variables were linear were test with Box-Tidwell method. Pearson correlation analysis were conducted to determine the relation between Lp(a), LDL-C and Gensini. All statistical analysis was performed with Stata version 15. It was considered statistically significant as P < 0.05.
3449 patients were invested in this study, of which 678 were distributed to Non-CAHD Group. Except male and diabetes, traditional CAHD risk factors, age, smoking, overweight, hypertension and family history were well matched between two groups (Table 1). Within all patients, 31.8% were divided to High-LDL-C Group. Clinical characteristics comparisons in subgroups was showed in Additional file 1: Tables S1 and S2.
Risk FACTORS for CAHD
As showed in Fig. 2, in the Logistic regression of all patients, 3 of 7 variables were risk factors of CAHD, which were diabetes (odds ratio (OR): 2.52, 95% confidence interval (95% CI): 1.08–5.86), LDL-C (OR: 1.05, 95%CI: 1.03–1.06), and Lp(a) (OR: 1.02, 95%CI: 1.01–1.03). In the Logistic regression of High-LDL-C group, 4 of 8 items turned to be risk factors for CAHD, which were age (OR: 1.15, 95%CI: 1.02–1.30), LDL-C (OR: 1.73, 95%CI: 1.70–1.77), non-HDL-C (OR: 1.45, 95%CI: 1.44–1.47), and ApoB (OR: 1.15, 95%CI: 1.13–1.16). While in Low-LDL-C group, among the 9 items, age (OR: 1.12, 95%CI: 1.07–1.18), Lp(a) (OR: 1.22, 95%CI: 1.17–1.28) and ApoB (OR: 1.13, 95%CI: 1.11–1.16) turned out to be CAHD risk factors (Fig. 2).
Lp(a)-Gensini correlation analysis
There were positive linear correlations between Lp(a) and Gensini In Low-LDL-C Group, High-LDL-C Group and total patients with the Spearman correlation coefficient r of 0.67, 0.32 and 0.41, (P < 0.001). Lp(a) was more relevant to Gensini in Low-LDL-C Group than the other two group (P < 0.001), but there was no significant difference between total patients and High-LDL-C Group (P = 0.07) (Fig. 3).
Lp(a)-Gensini and LDL-C-Gensini correlation in different LDL-C intervals
The LDL-C-Gensini correlation increased along with LDL-C concentration increase. While the correlation of Lp(a)-Gensini decreased with increasing LDL-C level (Fig. 4). The highest coefficient r of LDL-C-Gensini correlation was 0.64 in the LDL-C of 4.76–5.00 mmol/L, while the lowest r was 0.07 within the LDL-C of 2.51–2.75 mmol/L. The coefficient r of Lp(a)-Gensini correlation ranged in 0.02–0.57, with r = 0.02 in the LDL-C concentration of 2.51–2.75 mmol/L and r = 0.57 in 1.51–1.75 mmol/L. The fitted lines of LDL-C-Gensini and Lp(a)-Gensini correlation coefficient rs crossed near the point of LDL-C = 2.7 mmol/L. The LDL-C intervals were set as 0.25 mmol/L to meet the minimum request for Spearman correlation analysis, and the number of patients in different LDL-C intervals ranked from 35, in both 4.51–4.75 mmol/L and 5.01 mmol/L intervals, to 450 in 3.26–3.50 mmol/L.
In this study, we found the distinct CAHD risk factors in patients with different LDL-C levels. Moreover, in the correlation analysis, we found the linear correlation between Lp(a), LDL-C and Gensini and the correlation was influenced by LDL-C concentration. A meta-analysis of 49 clinical trials, over 312,000 patients, showed a great 23% MACE risk reduction achievement with 1 mmol/L LDL-C reduction in statin therapy . But under statin therapy background, additional LDL-C lowering with evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, achieved additional 60% LDL-C reduction but only 1.5% MACE risk reduction . Those results indicated that the clinical benefit of LDL-C lowering therapy descended with LDL-C decrease which is consistent with our finding in this study that the correlation between LDL-C and Gensini dropped with the LDL-C level decrease.
Even the Guideline recommended LDL-C concentration was strict for patients at very-high CVD risk, < 55 mg/dl, in both primary and secondary prevention . The data in the secondary prevention of vascular disease showed that the recurrent 10-year risk of vascular events is still over 30% in 9% patients with vascular disease, who’s risk factors were all at guideline-recommended targets . Lp(a) may contribute to the residual risk. In a recently published epidemiological study, Hu etc. fund the Lp(a) co-contributed with LDL-C to the incidence of acute myocardial infarction in Chinese people . In this study, we found the same trend, especially in patients with LDL-C < 100 mg/dL. In the subgroup analysis of Low-LDL-C Group in this study, near 43% patients were taking statin, the pathogenicity of Lp(a) may partly due to the effect of statins on Lp(a) increasing.
Lp(a) is mainly composed with an apolipoprotein a (apo(a)), an LDL like particle and phospholipid (PL). Under the stimulation of inflammation, LDL and PL enter the vascular endothelium and convert to oxidized LDL (Ox-LDL) and oxidized phospholipids (Ox-PL), which are critical in the process of atherosclerosis. Lp(a) can induce and accelerate atherothrombosis beyond its LDL components and is more effective than LDL in atherosclerosis inducing. However, 70–80% patients with the risk of CVD have low Lp(a) level and LDL-C present in significant excess to Lp(a), the LDL-driven CVD risk is mainly due to LDL-C. But the traditional clinical panel couldn’t distinguish Lp(a) from LDL-C, 30–45% of the reported LDL-C is contributed by Lp(a). In more extreme cases, the majority of LDL-C was carried by Lp(a) when LDL-C less than 25 mg/dL. In our study, Lp(a) showed no significant relation to CAHD in High-LDL-C Group but a strong relation to CAHD in patients with LDL-C < 100 mg/dL. That was partly because the weakened pathogenicity of LDL-C in the Low-LDL-C Group and the particle-enhanced turbidimetric immunoassay measurement of Lp(a), we adopted in this study.
The apo(a) component of Lp(a) contains three kringles, KII, KIV and KV. Among the 10 subtypes of KIV, KIV 1–10, there are large variations in the copies of KIV 2 domain, leading to over 40 different sizes of Lp(a). It was reported that over 80% individuals caring 2 different-size apo (a) isoforms . The common clinical report of Lp(a) was in total mass (mg/dL), but it has significant limitation of bias in measurement, considering the variable of Lp(a) components among patients. Thus, the National Heart, Lung, and Blood Institute (NHLBI) Working group recommended that Lp(a) should be reported in particle concentration . The measurement of Lp(a) in this study was based on a latex coated antibody of lipoprotein, Tina-quant Lipoprotein (a) Gen.2, which is free from the influence of Lpa(a) polymorphism, and the accuracy is higher among six common commercial measurements .
A prospective study suggested that the relationship between Lp(a) and CVD was a J-curve with a low slop when Lp(a) level was very low and sharply raised when Lp(a) level increased . Dr. Tsimikas thought the correlation of CVD risk and circulating Lp(a) mass is in a linear ship, when Lp(a) level increased over 25 mg/dl . As the result showed in this study, the molar concentration of Lp(a) correlated with coronary atherosclerotic lesions in a linear shape, but it was influenced by LDL-C level. We also noticed that both the correlations of Lp(a)-Gensini, and LDL-C-Gensini were weakest in LDL-C = 2.51–2.75 mmol/L, which is near to the recommended LDL-C level for patients with low CVD risk . The reason for that phenomenon may be the advantage number of non-statins intervened Non-CAHD patients in this subgroup.
In this study, we set the 50% coronary stenosis, measured in naked eye, as the as grouping basis. There would be errors in the grouping of patients with borderline lesions, without the intravascular imaging examination. 37% of the total patients in this study were under statin therapy and the duration of medication varied, the effect of statin on Lp(a) cannot be determined. In the correlation analysis of Lp(a)- Gensini and LDL-C-Gensini in different LDL-C intervals, the numbers of patients varied greatly among subgroups, leaded to unavoidable measurement bias. Besides, our study just proved the strong correlation between Lp(a) and CAHD in low LDL-C patients, but hardly confirm the clinical benefits of Lp(a) lowering intervention in those patients.
In this study, we found the Lp(a) was the risk factor of coronary atherosclerosis heart disease in patients with LDL-C < 100 mg/dL, rather than in patients with LDL-C ≥ 100 mg/dL. The correlation between Lp(a) and coronary atherosclerosis lesion was influenced by LDL-C concentration, and the correlation was stronger than LDL-C when LDL-C less than 104 mg/dl. In the patients with LDL-C < 104 mg/dL, whether the Lp(a) based intervention can achieve clinical benefits remains to be further studied.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Atherosclerotic cardiovascular disease
Low-density lipoprotein cholesterol
Major cardiovascular adverse event
Coronary atherosclerotic heart disease
Proprotein convertase subtilisin/kexin type 9
Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA Sr, Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631–9.
Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107.
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London). 2010;376(9753):1670–81.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.
Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129(6):635–42.
Nestel PJ, Barnes EH, Tonkin AM, Simes J, Fournier M, White HD, Colquhoun DM, Blankenberg S, Sullivan DR. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33(12):2902–8.
Albers JJ, Slee A, O’Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62(17):1575–9.
Emerging Risk Factors C, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG et al: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302(4):412–423.
Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102(10):1082–5.
Genser B, Dias KC, Siekmeier R, Stojakovic T, Grammer T, Maerz W. Lipoprotein (a) and risk of cardiovascular disease—a systematic review and meta analysis of prospective studies. Clin Lab. 2011;57(3–4):143–56.
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133–44.
Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57(11):1953–75.
Tsimikas S, Gordts P, Nora C, Yeang C, Witztum JL: Statin therapy increases lipoprotein(a) levels. Eur Heart J 2019.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.
Neeland IJ, Patel RS, Eshtehardi P, Dhawan S, McDaniel MC, Rab ST, Vaccarino V, Zafari AM, Samady H, Quyyumi AA. Coronary angiographic scoring systems: an evaluation of their equivalence and validity. Am Heart J. 2012;164(4):547–52.
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–97.
Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, Amarenco P, LaRosa JC, Cramer MJ, Westerink J, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation. 2016;134(19):1419–29.
Hu Y, Tao JY, Cai DP, He YM. Interaction of lipoprotein(a) with low-density lipoprotein cholesterol on first incident acute myocardial infarction. Clin Chim Acta. 2020;501:1–5.
Yeang C, Witztum JL, Tsimikas S. “LDL-C” = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol. 2015;26(3):169–78.
Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41(2):246–55.
Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, et al. NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018;71(2):177–92.
Scharnagl H, Stojakovic T, Dieplinger B, Dieplinger H, Erhart G, Kostner GM, Herrmann M, Marz W, Grammer TB. Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis. 2019;289:206–13.
Kotani K, Sakane N. Carotid intima-media thickness in asymptomatic subjects with low lipoprotein(a) levels. J Clin Med Res. 2012;4(2):130–4.
Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711.
The authors thank the participated patients, the director and researchers of the Cardiovascular Institute of Special Medical Center of Chinese People’s Armed Police Force.
This study was supported by Key Projects of Tianjin Natural Science Foundation, Tianjin, China (No. 16JCZDJC31900) and Special Project on Health Care of Logistics Support Department of the Central Military Commission, China (No. 20BJZ50).
Ethics approval and consent to participate
This study has been approved by the Ethics Committee of Special Medical Center of Chinese Armed Police Force. All the patients had been informed about the rights and obligations in this study and signed in informed consent before took part in.
Consent for publication
There was no competing interests to be declared.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplement Table 1. Baseline Characteristics Comparisons of Patients with LDL-C ≥ 100 mg/dL in Non-CAHD Group and CAHD Group. Supplement Table 2. Baseline Characteristics Comparisons of Patients with LDL-C < 100 mg/dL in Non-CAHD Group and CAHD Group.
About this article
Cite this article
Li, C., Chen, Q., Zhang, M. et al. The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL. BMC Cardiovasc Disord 21, 41 (2021). https://doi.org/10.1186/s12872-021-01861-6
- Low-density lipoprotein cholesterol
- Acute coronary syndrome
- Gensini score